Logo

Genentech's Esbriet (pirfenidone) Receives FDA's Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease

Share this

Genentech's Esbriet (pirfenidone) Receives FDA's Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease

Shots:

  • The US FDA’s BT designation is based on P-II study assessing Esbriet vs PBO in patients aged ≥18-85yrs. with progressive fibrosing uILD- an FVC of ≥45%- DLco of ≥30%- >10% fibrosis on high-resolution CT and a high-resolution CT from the previous 12mos.
  • The P-II study results: slowed disease progression; predicted median change in FVC measured by home spirometry (-87.7 vs -157.1 ml) @24wks.; DLco and 6MWD trended in favor of Esbriet; safety & tolerability profile is comparable with P-III studies in IPF
  • Esbriet is an oral therapy- indicated to treat IPF and has received EMA & the FDA’s approval for the treatment of mild to moderate IPF in 2011 & 2014 respectively

Click here ­to­ read full press release/ article | Ref: Genentech | Image: Nature


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions